Cibio PhD colloquium

5 May 2015
May 5th at 5pm
PhD Colloquia 2015

a forum between young researchers and scientists

This is a mini series of 6 seminars given by top experts in different fields covering almost all the area of the PhD program. Each colloquium is a friendly forum where students can learn how to communicate and critically evaluate science. Additionally, it is an opportunity to discuss ongoing research in an informal atmosphere and obtain valuable feedbacks from the experts.
PhD Colloquia bring together young scientists, senior scientists and students in a colloquial setting, encouraging interactions and exchanges of ideas.

The first seminar will take place on May 5th at 5 pm in the room B101 of the Polo Ferraris at Povo2.

Invited speaker:  Antonella Folgori  (ReiThera Srl, Rome)

Title: "Viruses as vectors for novel genetic vaccines: challenges and success from mice to humans.

Abstract:

Many viruses have been investigated for the development of genetic vaccines and the ideal ones must be endowed with many properties, such as the quality and the quantity of the immunological response induced against the encoded antigens, safety and production on a large scale basis. Viral based vaccines must also deal with the potential problem of the pre-existing anti-vector immunity. Several viral vaccine vectors have emerged to date, all of them having relative advantages and limits depending on the proposed application. Recent successes reflect diverse improvements such as development of new adenovirus serotypes and prime-boost regimes with different viral vectors to improve peak and longevity of adaptive immunity and induction of both humoral and cellular responses harnessing the ability of the different components of the immune system.
We have developed new recombinant adenoviral vectors derived from chimpanzees and combined them with other viral vectors in prime-boost regimes that are now lead vaccine candidates against Ebola, HCV, RSV and Malaria based on their potent induction of T and B cell immunity in humans and on demonstration of their efficacy in preclinical animal models. Challenges and success of the translation from preclinical to clinical development of some of these vaccine candidates will be discussed.

 

 

Download 
application/pdfPoster Cibio PhD Colloquia 2015(PDF | 686 KB)